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IsoxazolesAbstract 3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 3 was prepared by an
intramolecular cyclization of N-(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl) acetamide 2 in
ethanol in the presence of piperidine. N-allylation and N-propargyl alkylation of N-substituted
pyrazolo[3,4-d] pyrimidin-4(5H)-one 3 yielded the corresponding dipolarophiles 4 and 5 which
afford by condensation with arylnitrile oxides in toluene the expected new isoxazolines 6 and
isoxazoles 7, respectively. On the other hand, the aminopyrazole 1 in reﬂuxing with ethanol in
the presence of sodium hydroxide afforded the corresponding carboxamide 8, which then, was
converted to its ethyl 3-methyl-4-oxo-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d] pyrimidine-6-
carboxylate 9 with neat diethyl oxalate. The dipolarophile 10 on regiospeciﬁc 1,3-dipolar cycloaddition
with arylnitrile oxides affords isoxazoles 11 and the unexpected deethoxycarbonylated isoxazoles 12.
The target compounds were completely characterized by 1H NMR, 13C NMR, IR and HRMS.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Heterocycles display an array of signiﬁcant bioactive proper-
ties (Penning et al., 1997; Quiroga et al., 2008a,b) and are pres-
ent in a wide variety of drugs (Mekheimer et al., 2012). Among
the family of heterocyclic compounds, isoxazoles and isoxazo-
lines are an important class of ﬁve membered ring system, dis-
playing a wide variety of biological properties including
antiviral (Lee and Kim, 2002), antidepressant (Krompiec
et al., 2008) and anti-inﬂammatory activities (Dadiboyenarivatives
2 A. Rahmouni et al.and Nefzi, 2012). In fact, the isoxazolines possess signiﬁcant
synthetic applications (Vilela et al., 2011), diverse biological
properties (Soro et al., 2006) and represent a unique class of
pharmacophore present in many therapeutic agents
(Maheswari and Perumal, 2012). Also they showed, anti-tuber-
cular (Rakesh et al., 2009), antifungal (Basappa et al., 2003)
and anti-inﬂuenza effects (Kai et al., 2001). On the other hand,
isoxazole structural motif is found in the COX II inhibitors,
bextra and parecoxib because of its capability to exhibit a wide
range of bioactivities, including the anti-inﬂammatory and
antimicrobial activities (Dadiboyena and Nefzi, 2010;
Sobenina et al., 2005). For these reasons the synthesis of this
family of heterocycles continues to attract the attention of
synthetic organic and medicinal chemists.
A plethora of methodologies exist toward the synthesis of
isoxazoles and isoxazolines and most of them endeavor nitrile
oxide cycloaddition (NOC) as a key step (Cecchi et al., 2005;
Conti et al., 2010). Literature reports that, the intermolecular
[3+2] cycloaddition reaction of arylnitrile oxides with various
alkenes and alkynes represents an efﬁcient and convergent
method for the construction of such compounds, while this
strategy sometimes incurs problems in the yield and/or regio-
or stereoselectivity of the reaction.
On the other hand, the chemistry of pyrazolopyrimidine
and analogues has been a focus of intense research, due to their
widespread occurrence in drugs (Holla et al., 2006) and their
diversiﬁed biological activities (Dawood et al., 2008;
Oliveira-Campos et al., 2007). We report that N-Substituted
pyrazolopyrimidine derivatives have been extensively studied
but to the best of our knowledge there is no report of any
incorporating an isoxazoline or isoxazole moiety.
Taking into account the various biological activities of
isoxazolines, isoxazoles and pyrazolopyrimidines cited in the
literature, it appeared to us interesting to think about the
combination of these moieties hoping to access to more
biologically effective compounds.
As part of our continued interest in the development of
efﬁcient methods for the synthesis of biological heterocyclic
compounds, we report herein a facile and efﬁcient synthesis
of novel pyrazolo[3,4-d]pyrimidin-4(5H)-ones derivatives,
incorporating the isoxazoline or isoxazole moiety, in good
yields via 1,3-dipolar cycloaddition, in the hope they will be
a potent biologically and pharmacologically compounds.2. Results and discussion
Our ﬁrst key intermediate was the 5-aminopyrazole-4-carboni-
trile 1 which was easily prepared from condensation of
ethoxymethylenemalonitrile with phenylhydrazine (Youssef
et al., 2010). Compound 1 heated in acetic anhydride
(El-Enany et al., 2010; Rashad et al., 2009) afforded
N-(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)acetamide 2 in
75% which was identiﬁed on the basis of its spectral analyses.
The 1H NMR spectrum of compound 2 revealed signals at
2.28, 2.51 and 5.27 ppm due to two methyl groups and
amide-NH proton, respectively, in addition to an aromatic
multiplet in the region 7.33–7.52 ppm. The analysis of the
13C NMR spectrum revealed that the signal of the CN group
appeared at d 111.6 ppm and C‚O group at 170.9 ppm. The
intermediate 2 undergoes an intramolecular cyclization in the
presence of piperidine in ethanol to yield pyrazolopyrimidinonePlease cite this article in press as: Rahmouni, A. et al., Synthesis of novel isoxazolines
through [3+2] cycloaddition. Arabian Journal of Chemistry (2014), http://dx.doi.or3 (Scheme 1) (Ali, 2009). The IR spectrum of compound 3
revealed the presence of characteristic absorption bands at
1680 and 3240 cm1 assignable to carbonyl and NH functions,
respectively, beside the disappearance of the CN group absorp-
tion band. The disappearance of the cyano signal from the 13C
NMR spectrum of compound 3 is in favor of an intramolecu-
lar cyclization. Also, the structure of compound 3 was
supported by its ES-HRMS which showed a pseudo molecular
ion peak [M+H]+ at m/z 241.1083.
First, the required dipolarophiles 4 and 5 were, respectively,
prepared by N-allylation and N-propargylation (Mabrour
et al., 2007) of pyrazolopyrimidinone 3 (Scheme 1). Indeed,
in our investigation, dimethylformamide was found to be an
excellent solvent for the reaction of allyl and propargyl
bromide with pyrazolopyrimidinone 3, in the presence of
NaH. DMF is especially effective in this reaction for weaken-
ing the bromine–carbon bond. The N-allyl and N-propargyl
pyrazolopyrimidinones 4 and 5 were obtained in 78% and
80% yield, respectively. So the reaction is complete after 1 h
at room temperature.
Dipolarophiles 4 and 5 were then treated with various arylnit-
rile oxides generated in situ from aromatic oxime (Saad et al.,
2004; Tronchet et al., 1970) precursors under conventional
conditions furnished the desired isoxazolines 6a–f or isoxazoles
7a–g, respectively, in high yields (75–80%) (Scheme 2).
The structures of these compounds were conﬁrmed accord-
ing to their spectral data, where the IR spectra of compounds
6a–f indicated the existence of the isoxazoline C‚N group at
mmax = 1630–1640 cm
1. The 1H NMR spectra of 6a–f shows
duplication of most signals allowed to conclude the formation
of two diastereoisomers due to the presence of two asymmetric
centers, the alkylated nitrogen of pyrazolopyrimidinone and
the stereogenic center of isoxazoline. Attempts to separate
these diastereoisomers by chromatography were not success-
ful. In the 1H NMR spectrum of compound 6c as an example
we observed two singlets at 2.19 and 2.50 ppm attributable to
the methyl group protons (CH3)–8 while the two singlets of the
other methyl group protons (CH3)–9 resonate at 2.04 and
2.45 ppm. The same spectrum showed a multiplet centered at
4.91 ppm attributable to the CH stereogenic center and two
doublets of doublets at 3.17 ppm (J= 16.8 Hz, 7.2 Hz) and
at 3.43 ppm (J= 16.8 Hz, 10.5 Hz) corresponding to the
methylenic protons H40a/b of the ﬁrst diastereoisomer noted
A and two other doublets of doublets at 3.20 (J= 16.8 Hz,
9.0 Hz) and 3.46 ppm (J= 16.8 Hz, 10.2 Hz) attributable to
the same protons of the second diastereoisomer B. The
NACH2 protons of the mixture of the two diastereoisomers
appeared as for doublets of doublets at 2.84 ppm
(J= 14.1 Hz, 7.5 Hz) and at 4.23 ppm (J= 14.1 Hz, 5.1 Hz),
relative to the diastereoisomer A or B and at 3.55 ppm
(J= 14.7 Hz, 3.9 Hz) and at 3.99 ppm (J= 14.7 Hz, 6.0 Hz)
corresponding to the diastereoisomer B or A. The aromatic
protons in both diastereoisomers A and B exhibited a multiplet
at 7.03–7.54 ppm. 13C NMR spectrum of 6c exhibited a signal
at 50.2 ppm corresponding to NACH2 carbon and two signals
at 39.1 ppm and 78.6 ppm relative to the isoxazoline carbons
C40 and C50, respectively. The C‚N and carbonyl carbons
C30 and C4 resonated at 170.2 and 169.7 ppm, respectively.
The structures of compounds 6a–f were further conﬁrmed by
mass spectrometry.
The regioselectivity of this cycloaddition reaction generally
leads to a mixture of 1,4 and 1,5-regioisomers (Kiss et al.,and isoxazoles of N-substituted pyrazolo[3,4-d]pyrimidin-4(5H)- one derivatives
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Synthesis of novel isoxazolines and isoxazoles 32009). Although, in this study the novel 1,2,4-isoxazoline
derivatives 6a–f were formed as unique products, indicating
the regiospeciﬁcity of the reaction. Indeed, the nonformation
of the other 1,5-regioisomer was proven by the absence of
any duplication of signals on the spectra of 1H and 13C
NMR of the reaction crude and it may be explained by a
possible steric crowding factor.
Similarly, the IR spectrum of compound 7c showed an
absorption at mmax = 1611 cm
1 due to the isoxazole C‚N
bond. The 1H NMR spectrum of 7c showed two doublets at
4.37 ppm (J= 15.9 Hz) and at 5.08 ppm (J= 15.9 Hz)Please cite this article in press as: Rahmouni, A. et al., Synthesis of novel isoxazolines
through [3+2] cycloaddition. Arabian Journal of Chemistry (2014), http://dx.doi.orgattributed to the NACH2 protons. The C40-H isoxazole proton
resonated as a singlet at 6.53 ppm and all the aromatic protons
as a multiplet at 7.09–7.50 ppm. The 13C NMR spectrum
showed a signal at 42.5 ppm for the NACH2 carbon and two
signals at 102.5 ppm and 160.7 ppm for the two characteristic
isoxazole carbons C40 and C50, respectively. The C‚N and
carbonyl carbons C30 and C4 resonated at 152.4 ppm and
169.8 ppm, respectively. Mass spectrometry is also in
accordance with the proposed structure for compounds 7a–g.
As shown in Scheme 3, treatment of the aminopyrazole 1 in
reﬂuxing with ethanol in the presence of sodium hydroxideand isoxazoles of N-substituted pyrazolo[3,4-d]pyrimidin-4(5H)- one derivatives
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4 A. Rahmouni et al.afforded the corresponding carboxamide 8 with a yield of
80%. Then, 8 were converted to the pyrazolopyrimidinone 9
with neat diethyl oxalate under reﬂux. In order to access to
new isoxazole pyrazolopyrimidinones, the N-propargylation
of 9 afforded the dipolarophile 10 which was then subjected
to a reaction of 1,3-dipolar cycloaddition. The cycloaddition
reaction of arylnitrile oxides and dipolarophile 10, under con-
ventional conditions by reﬂuxing in toluene in the presence of
a catalytic amount of triethylamine for 8 h provided cycload-
ducts 11a–d in excellent to moderate yields (80–65%).
The structure of compound 10 was established on the basis
of its spectral data. The IR spectrum showed absorption bands
at 2100 cm1 (C„C), at 1670 cm1 (NAC‚O) and at
1720 cm1 (C‚O). The 1H NMR spectrum showed the
absence of the signal related to the mobile proton (ANHA)
and the observation of a doublet at 5.12 ppm (J= 2.4 Hz) rel-
ative to the methylene group (NACH2), a triplet at 2.33 ppm
(J= 2.4 Hz) attributable to the acetylenic proton (C„CAH)
and the presence of signals relative to the ester group. The cyc-
loadducts 11a–d were obtained and their structures were con-
ﬁrmed through spectral analysis where the IR spectrum of
compound 11b as an example indicated the existence of the
isoxazole C‚N group at mmax = 1620 cm
1. The 1H NMR
spectrum of 11b showed the disappearance of the C„CAH
characteristic signal, the appearance of a new singlet at
6.60 ppm characteristic of the C40-H isoxazole proton and the
presence of the speciﬁc signals of the ester group. The same
reaction of the dipolarophile 10 with the arylnitrile oxide main-
tained for 12 h, afforded the deethoxycarbonylated cycload-
ducts 12. The 1H NMR spectra showed the disappearance of
the characteristic signals of the ester group at position 6 indi-
cating that pyrazolopyrimidinones evolved into a carboxylic
acid form followed by a decarboxylation.Please cite this article in press as: Rahmouni, A. et al., Synthesis of novel isoxazolines
through [3+2] cycloaddition. Arabian Journal of Chemistry (2014), http://dx.doi.or3. Conclusion
In conclusion, this work reports the synthesis of N-allyl or
propargyl pyrazolo[3,4-d]pyrimidin-4(5H)-ones 4, 5 and 10,
in three steps starting from the key intermediate the aminopy-
razoles 1. In the second part we have described the successful
access to a new pyrazolo[3,4-d]pyrimidin-4(5H)-ones deriva-
tives, 6, 7, 11 and 12, incorporating the isoxazoline or isoxaz-
ole moiety in good yields via 1,3-dipolar cycloaddition of some
arylnitrile oxides and starting precursors 4, 5 and 10.
4. Experimental section
All melting points were determined on a Koﬂer-type micro-
scope and are uncorrected. IR spectra were recorded on a
Perkin–Elmer Fourier transform FT-IR spectrophotometer
(4000–400 cm1) using KBr pellets or CCl4 solution.
1H
NMR and 13C NMR spectra were recorded at room tempera-
ture (rt) in CDCl3 and dimethylsulfoxide (DMSO-d6) at
300 MHz and at 75 MHz, respectively, using residual nondeu-
terated solvent peaks as internal reference. Coupling constants
are given in Hz. HRMS spectra were acquired with an electro-
spray-time-of-ﬂight (ESI-TOF, LCT Premier XE, Waters)
mass spectrometer in the positive ion mode.
4.1. General procedure for the preparation of 3,6-dimethyl-1-
phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 3
Solution of 1 (0.01 mol), in acetic anhydride (20 mL) was
reﬂuxed for 6 h. The reaction mixture was evaporated under
vacuum and the obtained product was crystallized from
dichloromethane to give 2. A few drops of piperidine wereand isoxazoles of N-substituted pyrazolo[3,4-d]pyrimidin-4(5H)- one derivatives
g/10.1016/j.arabjc.2014.10.053
Synthesis of novel isoxazolines and isoxazoles 5added to an ethanolic solution (25 mL) of compound 2 and the
reaction mixture was reﬂuxed for 4 h. The solid product that
formed was ﬁltered off, dried, and puriﬁed by recrystallization
in EtOH to afford compound 3.
White crystals, yield 78%, mp: 277–279 C; IR (KBr,
cm1): 3240 (NH), 1680 (C‚O). 1H NMR (300 MHz, CDCl3):
d 2.51 (s, 3H, H9), 2.39 (s, 3H, H8), 7.40–7.51 (m, 5H, ArAH),
8.14 (s, 1H, ANHA). 13C NMR (75 MHz, CDCl3): d 13.0 (C8),
22.4 (C9), 113.1 (C3-a), 123.8, 127.8, 130.7, 137.1 (Carom), 139.7
(C7-a), 151.9 (C3), 160.2 (C6), 169.0 (C4). HRMS [M+H]
+
calcd for (C13H13N4O)
+ 241.1083, found 241.1089.
4.2. General procedure for N-allylation and N-propargylation of
3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
ones 4 and 5
The pyrazolopyrimidinone 3 (0.4 g) was added in portions to a
stirred suspension of NaH (0.1 g) in dry DMF (15 mL) at
20 C. After the addition was over, the mixture was stirred
at 20 C for 30 min. A solution of allyl bromide/propargyl
bromide (2 mL) in DMF (5 mL) was added dropwise to the
mixture at 20 C and the stirring was continued for 30 min.
The whole reaction mixture was poured into water (100 mL)
and extracted with EtOAc. The organic layer was dried and
concentrated in vacuo affording compounds 4 and 5,
respectively.
4.2.1. 5-Allyl-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one (4)
Yellowish liquid, yield 75%, IR (CCl4, cm
1): 1680 (C‚O),
1675 (C‚C), 3094 (CAH allyl). 1H NMR (300 MHz, CDCl3):
d 2.01 (s, 3H, H9), 2.39 (s, 3H, H8), 3.37 (dd, 1H, NACH2,
J= 7.2 Hz, J= 14.7 Hz), 4.57 (dd, 1H, NACH2,
J= 7.2 Hz, J= 14.7 Hz), 4.98–5.11 (m, ACH‚CH2), 5.67
(m, ACH‚CH2), 7.26–7.48 (m, 5H, ArAH).
13C NMR
(75 MHz, CDCl3): d 13.2 (C8), 21.9 (C9), 50.5 (NACH2),
112.3 (C3-a), 120.0 (ACH‚CH2), 130.9 (CH‚CH2), 120.5–
137.1 (Carom), 140.0 (C7-a), 144.2 (C3), 152.2 (C6), 169.3 (C4).
HRMS [M+H]+ calcd for (C16H17N4O)
+ 281.1399, found
281.1402.
4.2.2. 3,6-Dimethyl-1-phenyl-5-(prop-2-ynyl)-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one (5)
Yellowish liquid, yield 80%; IR (CCl4, cm
1): 1675 (C‚O),
3370 (CH propynyl). 1H NMR (300 MHz, CDCl3): d 1.93 (s,
3H, H9), 2.27 (t, 1H, AC„CAH, J= 2.4 Hz), 2.84 (s, 3H,
H8), 4.10–4.16 (dd, NACH2, J= 2.4 Hz, J= 17.4 Hz), 4.58–
4.64 (dd, NACH2, J= 2.4 Hz, J= 17.4 Hz), 7.31–7.47 (m,
5H, ArAH). 13C NMR (75 MHz, CDCl3): d 13.30 (C8), 22.2
(C9), 37.1 (NACH2), 67.9 (C11), 92.8 (C10), 111.9 (C3-a),
123.5–129.8 (Carom), 137.0 (C7-a), 143.2 (C3), 152.3 (C6),
168.8 (C4). HRMS [M+H]
+ calcd for (C16H15N4O)
+
279.1246, found 279.1247.
4.3. General procedure for the synthesis of isoxazolines 6a–f and
isoxazoles 7a–g
A mixture of dipolarophile 4 or 5 (3 eq) and arylnitrile oxide
(1 eq) was dissolved in toluene in the presence of a catalytic
amount of triethylamine, the solution was then reﬂuxed
for 8 h. The reaction was monitored with TLC after thePlease cite this article in press as: Rahmouni, A. et al., Synthesis of novel isoxazolines
through [3+2] cycloaddition. Arabian Journal of Chemistry (2014), http://dx.doi.orgcompletion of the reaction, the reaction mixture concentrated
and cooled. The product formed in each case was puriﬁed by
column chromatography using 9:1 mixture of chloroform
and ethylacetate to yield compounds 6 or 7.
4.3.1. 3,6-Dimethyl-1-phenyl-5-((3-pheny-4,5-dihydroisxazol-5-
yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (6a)
White crystals, yield 65%, mp: 125–127 C; IR (KBr, cm1):
1680 (C‚O), 1635 (isoxazoline C‚N). 1H NMR (300 MHz,
CDCl3): d 2.04–2.45 (2s, 3H, H9), 2.19–2.50 (2s, 3H, H8),
2.81 (dd, NACH2A/B, J= 14.1 Hz, 7.5 Hz), 4.21 (dd,
NACH2A/B, J= 14.1 Hz, 5.1 Hz), 3.54 (dd, NACH2A/B,
J= 14.7 Hz, 4.0 Hz), 3.97 (dd, NACH2A/B, J= 14.7 Hz,
6.0 Hz), 3.15 (dd, C40HaHb/A, J= 16.8 Hz, 7.2 Hz), 3.42
(dd, C40HaHb/A, J= 16.8 Hz, 10.5 Hz), 3.21 (dd, C40HaHb/
B, J= 16.8 Hz, 9.0 Hz), 3.45 (dd, C40HaHb/B, J= 16.8 Hz,
10.2 Hz), 4.90 (m, 1H, H50), 7.26–7.66 (m, 20H, ArAH).
13C
NMR (75 MHz, CDCl3): d 12.6 (C8), 21.5 (C9), 38.1(C40),
49.8 (N–CH2), 78.5 (C50), 111.5 (C3-a), 122.8–136.4 (Carom),
140.3 (C7-a), 143.4 (C3), 152.3 (C6), 166(C30), 169.4 (C4).
HRMS [M+H]+ calcd for (C23H22N5O2)
+ 400.1716, found
400.1729.4.3.2. 5-((3-(4-Methoxyphenyl)-4,5-dihydroisoxazol-5-
yl)methyl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one (6b)
White crystals, yield 75%, mp: 128–130 C; IR (KBr, cm1):
1679 (C‚O), 1630 (isoxazoline C‚N). 1H NMR (300 MHz,
CDCl3): d 2.04–2.44 (2s, 3H, H9), 2.18–2.50 (2s, 3H, H8),
2.81 (dd, NACH2A/B, J= 14.1 Hz, 7.5 Hz), 4.24 (dd,
NACH2A/B, J= 14.1 Hz, 5.1 Hz), 3.52 (dd, NACH2A/B,
J= 14.7 Hz, 3.9 Hz), 3.91 (dd, NACH2A/B, J= 14.7 Hz,
6.0 Hz), 3.84 (2s, 3H, AOCH3), 3.06 (dd, C40HaHb/A,
J= 16.8 Hz, 7.2 Hz), 3.41 (dd, C40HaHb/A, J= 16.8 Hz,
10.5 Hz), 3.11 (dd, C40HaHb/B, J= 16.8 Hz, 9.0 Hz), 3.47
(dd, C40HaHb/B, J= 16.8 Hz, 10.2 Hz), 4.88 (m, 1H, H50),
6.87–7.60 (m, 18H, ArAH). 13C NMR (75 MHz, CDCl3): d
12.7 (C8), 21.5 (C9), 38.6 (C40), 50.3 (NACH2), 54.8 (AOCH3),
78.1 (C50), 111.8 (C3-a), 122.8–158.3 (Carom), 141.6 (C7-a), 144.7
(C3), 152.3 (C6), 160.6(C30), 169.6 (C4). HRMS [M+H]
+ calcd
for (C24H24N5O3)
+ 430.1860, found 430.1879.4.3.3. 3,6-Dimethyl-1-phenyl-5-((3-(thiophen-2-yl)-4,5-
dihydroisoxazol-5-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-
4(5H)-one (6c)
White crystals, yield 75%, mp: 112–114 C; IR (KBr, cm1):
1680 (C‚O), 1635 (isoxazoline C‚N). 1H NMR (300 MHz,
CDCl3): d 2.04–2.45 (2s, 3H, H9), 2.19–2.50 (2s, 3H, H8),
2.84 (dd, NACH2A/B, J= 14.1 Hz, 7.5 Hz), 4.23 (dd,
NACH2A/B, J= 14.1 Hz, 5.1 Hz), 3.55 (dd, NACH2A/B,
J= 14.7 Hz, 3.9 Hz), 3.99 (dd, NACH2A/B, J= 14.7 Hz,
6.0 Hz), 3.17 (dd, C40HaHb/A, J= 16.8 Hz, 7.2 Hz), 3.43
(dd, C40HaHb/A, J= 16.8 Hz, 10.5 Hz), 3.20 (dd, C40HaHb/
B, J= 16.8 Hz, 9.0 Hz), 3.46 (dd, C40HaHb/B, J= 16.8 Hz,
10.2 Hz), 4.91 (m, 1H, H50), 7.03–7.54 (m, 16H, ArAH).
13C
NMR (75 MHz, CDCl3): d 12.8 (C8), 21.5 (C9), 39.1 (C40),
50.2 (NACH2), 78.6 (C50), 111.7 (C3-a), 122.8–151.7 (Carom),
143.6 (C7-a), 144.6 (C3), 152.3 (C6), 169.7 (C4), 170.2 (C30).
HRMS [M+H]+ calcd for (C21H20N5O2S)
+ 406.1338, found
406.1338.and isoxazoles of N-substituted pyrazolo[3,4-d]pyrimidin-4(5H)- one derivatives
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yl)methyl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one (6d)
White crystals, yield 73%, mp: 136–138 C; IR (KBr, cm1):
1675 (C‚O), 1640 (isoxazoline C‚N). 1H NMR (300 MHz,
CDCl3): d 1.91–2.37 (2s, 3H, H9), 2.1–2.43 (2s, 3H, H8), 2.75
(dd, NACH2A/B, J= 14.1 Hz, 7.5 Hz), 4.18 (dd, NACH2A/B,
J= 14.1 Hz, 5.1 Hz), 3.40 (dd, NACH2A/B, J= 14.7 Hz,
4.0 Hz), 3.96 (dd, NACH2A/B, J= 14.7 Hz, 6.0 Hz), 3.04 (dd,
C40HaHb/A, J= 16.8 Hz, 7.2 Hz), 3.40 (dd, C40HaHb/A,
J= 16.8 Hz, 10.5 Hz), 3.12 (dd, C40HaHb/B, J= 16.8 Hz,
9.0 Hz), 3.44 (dd, C40HaHb/B, J= 16.8 Hz, 10.2 Hz), 4.83
(m, 1H, H50), 7.21–7.52 (m, 18H, ArAH).
13C NMR (75 MHz,
CDCl3): d 12.8 (C8), 22.06 (C9), 37.5 (C40), 50.2 (NACH2),
79.2 (C50), 111.3 (C3-a), 122.8–136.3 (Carom), 143.6 (C7-a), 144.6
(C3), 155.3 (C6), 168.7 (C30), 170.6 (C4). HRMS [M+H]
+ calcd
for (C23H21ClN5O2)
+ 434.1379, found 434.1384.
4.3.5. 5-((3-(4-Ethylphenyl)-4,5-dihydroisoxazol-5-yl)methyl)-
3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
(6e)
White crystals, yield 70%, mp: 128–130 C; IR (KBr, cm1):
1680 (C‚O), 1637 (isoxazoline C‚N). 1H NMR (300 MHz,
CDCl3): d 1.17–1.27 (2t, 3H, J= 7.2 Hz, ACH2ACH3), 1.95–
2.36 (2s, 3H, H9), 2.41–2.59 (2q, 2H, J= 7.2 Hz,ACH2ACH3),
2.09–2.44 (2s, 3H, H8), 2.74 (dd, NACH2A/B, J= 14.1 Hz,
7.5 Hz), 4.15 (dd, NACH2A/B, J= 14.1 Hz, 5.1 Hz), 3.37 (dd,
NACH2A/B, J= 14.7 Hz, 3.9 Hz), 3.89 (dd, NACH2A/B,
J= 14.7 Hz, 6.0 Hz), 3.01 (dd, C40HaHb/A, J= 16.8 Hz,
7.2 Hz), 3.28 (dd, C40HaHb/A, J= 16.8 Hz, 10.5 Hz), 3.09
(dd, C40HaHb/B, J= 16.8 Hz, 9.0 Hz), 3.39 (dd, C40HaHb/
B, J= 16.8 Hz, 10.2 Hz), 4.80 (m, 1H, H50), 7.06–7.69 (m,
18H, ArAH). 13C NMR (75 MHz, CDCl3): d 13.2 (C8), 15.2
(ACH2ACH3), 22.0 (C9), 28.7 (ACH2ACH3), 38.0 (C40), 50.4
(NACH2), 78.2 (C50), 112.3 (C3-a), 120.8–137.3 (Carom), 144.2
(C7-a), 146.6 (C3), 152.1 (C6), 157.0 (C30), 170.5 (C4). HRMS
[M+H]+ calcd for (C25H26N5O2)
+ 428.2079, found 428.2087.
4.3.6. 3,6-Dimethyl-1-phenyl-5-((3-p-toly-4,5-dihydroisoxazol-
5-yl)methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (6f)
White crystals, yield 75%, mp: 132–134 C; IR (KBr, cm1):
1678 (C‚O), 1635 (isoxazoline C‚N). 1H NMR (300 MHz,
CDCl3): d 1.97–2.45 (2s, 3H, H9), 2.37–2.40 (2s, 3H, CH3),
2.19–2.51 (2s, 3H, H8), 2.82 (dd, NACH2A/B, J= 14.1 Hz,
7.5 Hz), 4.24 (dd, NACH2A/B, J= 14.1 Hz, 5.1 Hz), 3.55
(dd, NACH2A/B, J= 14.7 Hz, 3.9 Hz), 4.00 (dd, NACH2A/B,
J= 14.7 Hz, 6.0 Hz), 3.10 (dd, C40HaHb/A, J= 16.8 Hz,
7.2 Hz), 3.40 (dd, C40HaHb/A, J= 16.8 Hz,7.2 Hz), 3.15
(dd, C40HaHb/B, J= 16.8 Hz,7.2 Hz), 3.44 (dd, C40HaHb/B,
J= 16.8 Hz,7.2 Hz), 4.91 (m, 1H, H50), 7.10–7.63 (m, 18H,
ArAH). 13C NMR (75 MHz, CDCl3): d 12.8 (C8), 21.0
(CH3), 21.5 (C9), 38.5 (C40), 50.3 (NACH2), 78.2 (C50), 111.8
(C3-a), 122.8–140.1 (Carom), 144.7 (C7-a), 151.7 (C3), 156.5
(C6), 162.7 (C30), 170.1 (C4). HRMS [M+H]
+ calcd for
(C24H24N5O2)
+ 414.1930, found 414.1930.
4.3.7. 3,6-Dimethyl-1-phenyl-5-((3-phenylisxazol-5-yl)methyl)-
1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (7a)
White crystals, yield 70%, mp: 122–124 C; IR (KBr, cm1):
1680 (C‚O), 1611 (isoxazole C‚N). 1H NMR (300 MHz,Please cite this article in press as: Rahmouni, A. et al., Synthesis of novel isoxazolines
through [3+2] cycloaddition. Arabian Journal of Chemistry (2014), http://dx.doi.orCDCl3): d 2.14 (s, 3H, H9), 2.46 (s, 3H, H8), 4.40 (d, NACH2,
J= 15.6 Hz), 5.09 (d, NACH2, J= 15.6 Hz), 6.55 (s, 1H,
H40), 7.26–7.66 (m, 10H, ArAH).
13C NMR (75 MHz, CDCl3):
d 13.2 (C8), 21.8 (C9), 42.1 (NACH2), 102.4 (C40), 111.6 (C3-a),
123.5–136.7 (Carom), 140.3 (C7-a), 143.4 (C3), 151.2 (C6), 162.7
(C50), 166 (C4), 169.4 (C30). HRMS [M+H]
+ calcd for
(C23H20N5O2)
+ 398.1172, found 398.1179.
4.3.8. 5-((3-(4-Methoxyphenyl)isoxazol-5-yl)methyl)-3,6-
dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
(7b)
White crystals, yield 75%, mp: 124–126 C; IR (KBr, cm1):
1679 (C‚O), 1614 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 2.10 (s, 3H, H9), 2.41 (s, 3H, H8), 3.41 (s, 3H,
AOACH3), 4.32 (d, NACH2, J= 15.6 Hz), 5.09 (d, NACH2,
J= 15.6 Hz), 6.50 (s, 1H, H40), 7.24–7.61 (m, 9H, ArAH).
13C NMR (75 MHz, CDCl3): d 13.3 (C8), 21.7 (C9), 42.1
(NACH2), 54.8 (AOCH3), 101.1 (C40), 111.8 (C3-a), 123.5–
160.7 (Carom), 142.2 (C7-a), 143.7 (C3), 151.2 (C6), 162.1 (C50),
168.7 (C4), 169.5 (C30). HRMS [M+H]
+ calcd for
(C24H22N5O3)
+ 428.1672, found 428.1678.
4.3.9. 3,6-Dimethyl-1-phenyl-5-((3-(thiophen-2-yl)isoxazol-5-
yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (7c)
White crystals, yield 80%, mp: 110–112 C; IR (KBr, cm1):
1675 (C‚O), 1611 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 2.10 (s, 3H, H9), 2.41 (s, 3H, H8), 4.37 (d, NACH2,
J= 15.6 Hz), 5.08 (d, NACH2, J= 15.6 Hz), 6.53 (s, 1H,
H40), 7.09–7.50 (m, 8H, ArAH).
13C NMR (75 MHz, CDCl3):
d 13.27 (C8), 22.1 (C9), 42.5 (NACH2), 102.5 (C40), 111.5 (C3-a),
123.1–136.7 (Carom), 143.2 (C7-a), 152.1 (C3), 152.4 (C30), 158.1
(C6), 160.7(C50), 169.8 (C4). HRMS [M+H]
+ calcd for
(C21H18N5O2S)
+ 404.1181, found 404.1195.
4.3.10. 5-((3-(4-Chlorophenyl)isoxazol-5-yl)methyl)-3, 6-
dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
(7d)
White crystals, yield 78%, mp: 138–140 C; IR (KBr, cm1):
1680 (C‚O), 1613 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 2.15 (s, 3H, H9), 2.45 (s, 3H, H8), 4.33 (d, NACH2,
J= 15.6 Hz), 5.14 (d, NACH2, J= 15.6 Hz), 6.58 (s, 1H,
H40), 7.34–7.71 (m, 9H, ArAH).
13C NMR (75 MHz, CDCl3):
d 13.23 (C8), 21.8 (C9), 42.6 (NACH2), 102.3 (C40), 111.8 (C3-a),
123.1–136.8 (Carom), 143.3 (C7-a), 147.1 (C3), 152.4 (C6), 161.8
(C50), 166.6 (C4), 169.5 (C30). HRMS [M+H]
+ calcd for
(C23H19ClN5O2)
+ 432.1227, found 432.1231.
4.3.11. 5-((3-(4-Ethylphenyl)isoxazol-5-yl)methyl)-3,6-
dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
(7e)
White crystals, yield 70%, mp: 144–146 C; IR (KBr, cm1):
1675 (C‚O), 1614 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 1.41 (t, 3H, J= 7.2 Hz, ACH2ACH3), 2.10 (s,
3H, H9), 2.44 (q, 2H, J= 7.2 Hz, ACH2ACH3), 2.51 (s, 3H,
H8), 4.30 (d, NACH2, J= 15.6 Hz), 5.01 (d, NACH2,
J= 15.6 Hz), 6.52 (s, 1H, H40), 7.21–7.77 (m, 9H, ArAH).
13C NMR (75 MHz, CDCl3): d 13.3 (C8), 13.8 (ACH2ACH3),
22.1 (C9), 31.8 (ACH2ACH3), 41.8 (NACH2), 100.1 (C40),
111.1 (C3-a), 123.5–137.7 (Carom), 142.1 (C7-a), 143.1 (C3),and isoxazoles of N-substituted pyrazolo[3,4-d]pyrimidin-4(5H)- one derivatives
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Synthesis of novel isoxazolines and isoxazoles 7151.1 (C6), 162.2 (C50), 168.6 (C4), 169.4 (C30). HRMS
[M+H]+ calcd for (C25H24N5O2)
+ 426.1885, found 426.1885.
4.3.12. 3,6-Dimethyl-1-phenyl-5-((3-p-tolylisxazol-5-yl)methyl-
1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (7f)
White crystals, yield 75%, mp: 140–142 C; IR (KBr, cm1):
1680 (C‚O), 1612 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 2.14 (s, 3H, H9), 2.40–2.46 (s, 2CH3, H8 and Ph-
CH3), 4.40 (d, NACH2, J= 15.6 Hz), 5.12 (d, NACH2,
J= 15.6 Hz), 6.57 (s, 1H, H40), 7.34–7.71 (m, 9H, ArAH).
13C NMR (75 MHz, CDCl3): d 13.22 (C8), 21.4 (C9), 21.8
(Ph-CH3), 42.5 (NACH2), 102.3 (C40), 111.6 (C3-a), 123.5–
136.8 (Carom), 140.3 (C7-a), 144.1 (C3), 152.4 (C6), 162.7 (C50),
166.0 (C4), 169.4 (C30). HRMS [M+H]
+ calcd for
(C24H22N5O2)
+ 412.1774, found 412.1783.
4.3.13. 5-((3-(4-Isopropylphenyl)isoxazol-5-yl)methyl)-3,
6-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
(7g)
White crystals, yield 80%, mp: 137–139 C; IR (KBr, cm1):
1680 (C‚O), 1611 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 1.16–120 (s, 6H, ACHA(CH3)2), 2.04 (s, 3H, H9),
2.41 (s, 3H, H8), 2.86 (m, 1H, ACHA(CH3)2), 4.30 (d,
NACH2, J= 15.9 Hz), 5.01 (d, NACH2, J= 15.9 Hz), 6.49
(s, 1H, H40), 7.18–7.61 (m, 9H, ArAH).
13C NMR (75 MHz,
CDCl3): d 13.22 (C8), 21.9 (C9), 23.8 (ACHA(CH3)2), 34.0
(ACHA(CH3)2), 42.5 (NACH2), 102.4 (C40), 111.8 (C3-a),
123.5–143.4 (Carom), 151.2 (C7-a), 152.3 (C3), 162.7 (C6),
166.0 (C50), 168.8 (C4), 169.4 (C30). HRMS [M+H]
+ calcd
for (C26H26N5O2)
+ 440.2087, found 440.2101.
4.4. General procedure for the preparation of 5-Amino-3-methyl-
1-phenyl-1H-pyrazole-4-carboxamide 8
To a solution of 1 (1.22 g, 11.3 mmol) in ethanol (10.0 mL) was
added dropwise a solution of 33.3% sodium hydroxide
(12.0 mL). The mixture was then heated under reﬂux for 6 h.
After cooling to room temperature, the reaction mixture was
concentrated under vacuum and 6 M HCl solutions was added
until pH 4. After cooling in ice water for 4 h, the precipitated
solid was ﬁltered, washed with water and dried to yield com-
pound 8.
Yellowish solid, yield 80%, mp: 260–262 C; IR (KBr,
cm1): 1675 (C‚O), 3483–3219 (NH2).
1H NMR (300 MHz,
DMSO-d6): d 3.51 (s, 3H, CH3), 6.41 (s, 2H, NH2), 6.71 (s,
2H, NH2), 7.33–7.56 (m, 5H, ArAH).
13C NMR (75 MHz,
DMSO-d6): d 14.4 (CH3), 96.2 (C4), 122.9–138.1 (Carom),
146.2 (C3), 150.3 (C5), 166.9 (C‚O).
4.5. General procedure for the preparation of ethyl 3-methyl-4-
oxo-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine-6-
carboxylate 9
A mixture of 8 (2.50 g, 12.40 mmol) and diethyl oxalate
(8.2 mL) was reﬂuxed for 5 h and the reaction mixture was
allowed to cool to room temperature. The precipitate was
collected, washed with petroleum ether and dried to give
compound 9.
White solid, yield 60%, mp: 132–134 C; IR (KBr, cm1):
1680 (C‚O), 3195 (NH2).
1H NMR (300 MHz, CDCl3): dPlease cite this article in press as: Rahmouni, A. et al., Synthesis of novel isoxazolines
through [3+2] cycloaddition. Arabian Journal of Chemistry (2014), http://dx.doi.org1.47 (t, 3H, J= 6.9 Hz, AOACH2ACH3), 2.70 (s, 3H, H8),
4.53 (q, 2H, J= 6.9 Hz, AOACH2ACH3), 7.26–8.07 (m, 5H,
ArAH), 10.50 (s, 1H, ANHA). 13C NMR (75 MHz, CDCl3):
d 13.0 (AOACH2ACH3), 13.5 (CH3), 63.5 (AOACH2ACH3),
106.5 (C3-a), 121.5–137.7 (Carom), 146.9 (C7-a), 150.8 (C3),
157.1 (C6), 159.4 (C‚O). HRMS [M+H]
+ calcd for
(C15H15N4O3)
+ 299.1063, found 299.1066.4.6. General procedure for the preparation of ethyl 3-methyl-4-
oxo-1-phenyl-5-(prop-2-ynyl)-4, 5-dihydro-1H-pyrazolo[3,4-
d]pyrimidine-6-carboxylate 10
The pyrazolopyrimidinone 9 (0.4 g) was added in portions to a
stirred suspension of NaH (0.1 g) in dry DMF (15 mL) at 0 C.
After the addition was over, the mixture was stirred at 0 C for
30 min. A solution of propargyl bromide (2 mL) in DMF
(5 mL) was added dropwise to the mixture at 20 C and the
stirring was continued for 30 min. The whole reaction mixture
was poured into water (100 mL) and extracted with EtOAc.
The organic layer was dried and concentrated in vacuo afford-
ing compound 10.
Yellowish liquid, yield 78%; IR (CCl4, cm
1): 2100 (C„C),
1720 (C‚O), 1670 (NAC‚O), 1H NMR (300 MHz, CDCl3):
d 1.48 (t, 3H, J= 7.2 Hz, ACH2ACH3), 2.33 (t, 1H,
AC„CAH, J= 2.4 Hz), 2.76 (s, 3H, H8), 4.50 (q, 2H,
J= 6.9 Hz, ACH2ACH3), 4.12 (d, NACH2, J= 2.4 Hz),
7.33–8.05 (m, 5H, ArAH). 13C NMR (75 MHz, CDCl3): d
13.01 (ACH2ACH3), 13.4 (C8), 37.8 (NACH2), 63.0 (ACH2-
ACH3), 72.6 (C10), 78.1 (C11), 104.7 (C3-a), 121.4–137.6
(Carom), 147.1 (C7-a), 148.9 (C3), 156.3 (C9), 160.4 (C4). HRMS
[M+H]+ calcd for (C18H17N4O3)
+ 337.1250, found 337.1256.4.7. General procedure for the preparation of cycloadducts
11a–d and 12a–d
A mixture of dipolarophile 10 (1 eq) with arylnitrile oxide
(1 eq) in toluene in the presence of a catalytic amount of trieth-
ylamine was reﬂuxed for 8 h. The reaction was monitored with
TLC after the completion of the reaction, the reaction mixture
concentrated and cooled. The products 11 formed were
puriﬁed by column chromatography using 8.5:1.5 mixtures of
chloroform and ethylacetate. The above same reaction
maintained for 12 h afforded the deethoxycarbonylated
cycloadducts 12.
4.7.1. Ethyl 3-methyl-4-oxo-1-phenyl-5-((3-p-tolylisoxazol-5-
yl)methyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine-6-
carboxylate (11a)
White crystals, yield 78%, mp: 143–145 C; IR (KBr, cm1):
1680 (C‚O), 1615 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 1.43 (t, 3H, J= 7.2 Hz, AOACH2ACH3), 2.28 (s,
3H, CH3), 2.73 (s, 3H, H8), 4.50 (q, 2H, J= 6.9 Hz,
AOACH2ACH3), 5.63 (s, 2H, NACH2), 6.58 (s, 1H, H40),
7.30–8.01 (m, 9H, ArAH). 13C NMR (75 MHz, CDCl3): d
13.01 (AOACH2ACH3), 13.8 (C8), 37.8 (NACH2), 63.0
(OACH2ACH3), 100.1 (C40), 111.2 (C3-a), 123.5–137.7 (Carom),
140.1 (C6), 142.1 (C7-a), 147.1 (C3), 156.6 (C50), 160.2 (C9),
161.2 (C4), 166.6 (C30). HRMS [M+H]
+ calcd for
(C26H24N5O4)
+ 470.1780, found 470.1784.and isoxazoles of N-substituted pyrazolo[3,4-d]pyrimidin-4(5H)- one derivatives
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methyl-4-oxo-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidine-6-carboxylate (11b)
White crystals, yield 78%, mp: 147–149 C; IR (KBr, cm1):
1678 (C‚O), 1620 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 1.43 (t, 3H, J= 7.2 Hz, AOACH2ACH3), 2.71 (s,
3H, H8), 4.52 (q, 2H, J= 6.9 Hz, AOACH2ACH3), 5.66 (s,
2H, NACH2), 6.60 (s, 1H, H40), 7.34–8.01 (m, 9H, ArAH).
13C NMR (75 MHz, CDCl3): d 13.04 (AOACH2ACH3),
13.36 (C8), 37.9 (NACH2), 63.3 (OACH2ACH3), 101.3 (C40),
111.1 (C3-a), 121.5–137.7 (Carom), 140.2 (C6), 143.1 (C7-a),
147.09 (C3), 157.6 (C50), 160.5 (C9), 161.3 (C4), 166.6 (C30).
HRMS [M+H]+ calcd for (C25H21ClN5O4)
+ 490.1282, found
490.1294.
4.7.3. Ethyl 5-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)-3-
methyl-4-oxo-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidine-6-carboxylate (11c)
White crystals, yield 78%, mp: 144–146 C; IR (KBr, cm1):
1677 (C‚O), 1618 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 1.41 (t, 3H, J= 7.2 Hz, AOACH2ACH3), 2.69 (s,
3H, H8), 3.58 (s, 3H, CH3), 4.54 (q, 2H, J= 6.9 Hz,
AOACH2ACH3), 5.64 (s, 2H, NACH2), 6.61 (s, 1H, H40),
7.36–8.04 (m, 9H, ArAH). 13C NMR (75 MHz, CDCl3): d
13.01 (AOACH2ACH3), 13.40 (C8), 38.1 (NACH2), 54.2
(CH3), 63.6 (OACH2ACH3), 101.2 (C40), 111.0 (C3-a), 122.5–
137.8 (Carom), 141.7 (C6), 143.2 (C7-a), 147.1 (C3), 157.8 (C50),
160.6 (C9), 161.7 (C4), 166.8 (C30). HRMS [M+H]
+ calcd
for (C26H24N5O5)
+ 486.1730, found 486.1733.4.7.4. Ethyl 5-((3-(4-isopropylphenyl)isoxazol-5-yl)methyl)-3-
methyl-4-oxo-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidine-6-carboxylate (11d)
White crystals, yield 80%, mp: 138–140 C; IR (KBr, cm1):
1680 (C‚O), 1620 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 1.27 (s, 6H, ACH-(CH3)2), 1.46 (t, 3H,
J= 7.2 Hz, AOACH2ACH3), 2.72 (s, 3H, H8), 2.93 (m, 1H,
ACHA(CH3)2), 4.51 (q, 2H, J= 6.9 Hz, AOACH2ACH3),
5.67 (s, 2H, NACH2), 6.59 (s, 1H, H40), 7.23–8.04 (m, 9H,
ArAH). 13C NMR (75 MHz, CDCl3): d 13.01 (AOACH2-
ACH3), 13.36 (C8), 23.3 (ACHA(CH3)2), 32.7
(ACHA(CH3)2), 37.8 (NACH2), 63.3 (OACH2ACH3), 101.4
(C40), 110.0 (C3-a), 121.5–148.5 (Carom), 141.7 (C6), 143.2
(C7-a), 154.7 (C3), 156.8 (C50), 160.6 (C9), 163.3 (C4), 166.0
(C30). HRMS [M+H]
+ calcd for (C28H28N5O4)
+ 498.2080,
found 498.2087.4.7.5. 3-Methyl-1-phenyl-5-((3-p-tolylisoxazol-5-yl)methyl)-
1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (12a)
White crystals, yield 80%, mp: 142–144 C; IR (KBr, cm1):
1680 (C‚O), 1620 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 2.40 (s, 3H, CH3), 2.69 (s, 3H, H8), 5.33 (s, 2H,
NACH2), 6.67 (s, 1H, H40), 7.30–8.01 (m, 9H, ArAH), 8.19
(s, 1H, H6).
13C NMR (75 MHz, CDCl3): d 13.8 (C8), 20.9
(CH3), 39.8 (NACH2), 101.8 (C40), 104.9 (C3-a), 121.6–140.0
(Carom), 146.7 (C7-a), 148.2 (C6), 150.9 (C3), 156.7 (C50), 162.4
(C4), 165.4 (C30). HRMS [M+H]
+ calcd for (C23H19N5O2)
+
398.1605, found 398.1617.Please cite this article in press as: Rahmouni, A. et al., Synthesis of novel isoxazolines
through [3+2] cycloaddition. Arabian Journal of Chemistry (2014), http://dx.doi.or4.7.6. 5-((3-(4-Chlorophenyl)isoxazol-5-yl)methyl)-3-methyl-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (12b)
White crystals, yield 70%, mp: 148–150 C; IR (KBr, cm1):
1678 (C‚O), 1618 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 2.70 (s, 3H, H8), 5.38 (s, 2H, NACH2), 6.65 (s,
1H, H40), 7.29–8.1 (m, 9H, ArAH), 8.21 (s, 1H, H6).
13C
NMR (75 MHz, CDCl3): d 14.1 (C8), 39.6 (NACH2), 99.9
(C40), 105.1 (C3-a), 121.4–140.1 (Carom), 146.6 (C7-a), 148.1
(C6), 150.8 (C3), 156.5 (C50), 162.1 (C4), 165.4 (C30). HRMS
[M+H]+ calcd for (C22H17ClN5O2)
+ 418.1020, found
418.1024.
4.7.7. 5-((3-(4-Methoxyphenyl)isoxazol-5-yl)methyl)-3-
methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
(12c)
White crystals, yield 73%, mp: 140–142 C; IR (KBr, cm1):
1680 (C‚O), 1615 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 2.70 (s, 3H, H8), 3.82 (s, 3H, AOCH3), 5.30 (s,
2H, NACH2), 6.66 (s, 1H, H40), 7.27–8.0 (m, 9H, ArAH),
8.20 (s, 1H, H6).
13C NMR (75 MHz, CDCl3): d 13.8 (C8),
20.9 (CH3), 39.6 (NACH2), 54.8 (AOCH3), 101.6 (C40), 105.1
(C3-a), 121.4–139.8 (Carom), 146.5 (C7-a), 148.3 (C6), 149.9
(C3), 156.5 (C50), 162.1 (C4), 165.3 (C30). HRMS [M+H]
+
calcd for (C23H20N5O3)
+ 414.1518, found 414.1521.
4.7.8. 5-((3-(4-Isopropylphenyl)isoxazol-5-yl)methyl)-3-
methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
(12d)
White crystals, yield 78%, mp: 136–138 C; IR (KBr, cm1):
1679 (C‚O), 1620 (isoxazole C‚N). 1H NMR (300 MHz,
CDCl3): d 1.25 (s, 6H, ACHA(CH3)2), 2.73 (s, 3H, H8), 2.95
(m, 1H, ACHA(CH3)2), 5.30 (s, 2H, NACH2), 6.66 (s, 1H,
H40), 7.27–8.0 (m, 9H, ArAH), 8.20 (s, 1H, H6).
13C NMR
(75 MHz, CDCl3): d 13.8 (C8), 20.9 (CH3), 39.6 (NACH2),
54.8 (AOCH3), 101.6 (C40), 105.1 (C3-a), 121.4–139.8 (Carom),
146.5 (C7-a), 148.3 (C6), 149.9 (C3), 156.5 (C50), 162.1 (C4),
165.3 (C30). HRMS [M+H]
+ calcd for (C25H24N5O2)
+
426.1880, found 426.1885.
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